drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous CD30-targeted antibody–drug conjugate that is internalized upon CD30 binding and releases a camptothecin-based topoisomerase I inhibitor payload, inhibiting Topo I, disrupting DNA replication, and inducing DNA damage/apoptosis; studied as monotherapy in adults with advanced CD30+ lymphomas.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
PF-08046044/SGN-35C is a CD30-targeted antibody–drug conjugate. After binding CD30 on tumor cells and internalization, it releases a camptothecin-based topoisomerase I inhibitor payload that inhibits Topo I, disrupts DNA replication, and induces DNA damage leading to apoptosis.
drug_name
PF-08046044/SGN-35C
nct_id_drug_ref
NCT06254495